TMC-278
Introduction
TMC-278 ("Tibotec medical compound") is a type of drug that is part of the DAPY family. It was developed by Johnson & Johnson and Rutgers University to treat HIV. Particularly, it acts as a non-nucleoside reverse transcriptase inhibitor; in effect, halting the reproductive-ability of the virus. At this point in time, TMC-114 (Darunavir) has been approved under the name Prezista®; whereas, TMC-120 and TMC-125 are in development.[1]